Rigel Pharmaceuticals Inc (RIGL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Rigel Pharmaceuticals Inc (RIGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9920
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. Tavalisse (fostamatinib disodium hexahydrate), the company’s first US FDA approved product is an oral spleen tyrosine kinase inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia. Rigel is also evaluating Fostamatinib for autoimmune hemolytic anemia and IgA nephropathy in Phase II trials. The company also has partnered clinical programs with Aclaris, BerGenBio, Daiichi, AstraZeneca and Bristol-Myers Squibb. Rigel is headquartered in South San Francisco, California, the US.

Rigel Pharmaceuticals Inc (RIGL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Bristol-Myers Squibb to Terminate R&D Agreement with Rigel Pharma 11
Licensing Agreements 12
Kissei Pharma Enters into Licensing Agreement with Rigel Pharma 12
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 13
AstraZeneca Enters Into Licensing Agreement With Rigel Pharma For R256 14
Equity Offering 15
Rigel Pharma Prices Public Offering of Shares for USD62.4 Million 15
Rigel Pharma Raises USD69.7 Million in Public Offering of Shares 16
Rigel Pharma Raises USD3.4 Million in Public Offering of Shares 18
Rigel Pharma Raises USD46 Million in Public Offering of Shares 19
Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 21
Rigel Pharma Completes Public Offering Of Shares For US$145 Million 22
Rigel Pharmaceuticals Inc – Key Competitors 24
Rigel Pharmaceuticals Inc – Key Employees 25
Rigel Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 08, 2018: Rigel Pharmaceutical reports second quarter 2018 financial results 27
May 01, 2018: Rigel Reports First Quarter 2018 Financial Results 28
Mar 06, 2018: Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update 30
Nov 07, 2017: Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update 32
Aug 01, 2017: Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update 33
May 02, 2017: Rigel Announces First Quarter 2017 Financial Results and Provides Company Update 34
Mar 07, 2017: Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results 36
Corporate Communications 38
Dec 15, 2017: Rigel Announces Departure of Chief Financial Officer 38
Nov 02, 2017: Rigel Welcomes Gregg Lapointe to Board of Directors 39
Aug 25, 2017: Rigel Welcomes Brian Kotzin, M.D. to Board of Directors 40
Product News 41
04/17/2018: Rigel Announces FDA Approval of TAVALISSE (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients 41
04/12/2018: Rigel Makes Statement Regarding Website Error 42
01/30/2017: Fostamatinib Study Results Continue to Trend Positive 43
Product Approvals 44
Oct 02, 2017: Rigel Provides Update on FDA Review of Fostamatinib for ITP 44
Jun 19, 2017: FDA Accepts Rigels New Drug Application for TAVALISSE (fostamatinib disodium) for the Treatment of Chronic ITP 45
Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States 46
Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP 47
Clinical Trials 48
Jun 26, 2018: Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases 48
Apr 30, 2018: TAVALISSE (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo 49
Apr 03, 2018: Rigel Announces Topline Data From Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy 50
Mar 01, 2018: Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America 51
Jan 04, 2018: Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference 52
Dec 08, 2017: Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting 54
Oct 03, 2017: Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia Phase 2 Study 55
Jun 22, 2017: Rigel Announces Oral Presentation of TAVALISSE Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rigel Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Bristol-Myers Squibb to Terminate R&D Agreement with Rigel Pharma 11
Kissei Pharma Enters into Licensing Agreement with Rigel Pharma 12
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 13
AstraZeneca Enters Into Licensing Agreement With Rigel Pharma For R256 14
Rigel Pharma Prices Public Offering of Shares for USD62.4 Million 15
Rigel Pharma Raises USD69.7 Million in Public Offering of Shares 16
Rigel Pharma Raises USD3.4 Million in Public Offering of Shares 18
Rigel Pharma Raises USD46 Million in Public Offering of Shares 19
Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 21
Rigel Pharma Completes Public Offering Of Shares For US$145 Million 22
Rigel Pharmaceuticals Inc, Key Competitors 24
Rigel Pharmaceuticals Inc, Key Employees 25

List of Figures
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Rigel Pharmaceuticals Inc (RIGL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Arete Industries Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Arete Industries Inc (Arete Industries) is an oil and gas company that operates pipeline stations. The company operates a natural gas gathering system located in Campbell County, Wyoming. Its gas gathering systems contains coated steel pipeline transporting coal bed methane. Arete Industries …
  • Nordic Nanovector ASA (NANO):企業の財務・戦略的SWOT分析
    Summary Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of haematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed fo …
  • Genuine Parts Company (GPC):企業の財務・戦略的SWOT分析
    Genuine Parts Company (GPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Riot Blockchain Inc (RIOT):企業の財務・戦略的SWOT分析
    Riot Blockchain Inc (RIOT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Medigard Ltd (MGZ):医療機器:M&Aディール及び事業提携情報
    Summary Medigard Ltd (Medigard), formerly Medisafe Instruments Pty Ltd, is a medical device company that designs and develops retractable safety medical devices. The company provides products such as auto-retractable syringe, manual retractable syringe, blood collection device, intravenous valve and …
  • KineMed Inc-医療機器分野:企業M&A・提携分析
    Summary KineMed Inc (KineMed) is a biotechnology company that develops and commercializes proprietary biomarker platform technology. The company applies its proprietary biomarker platform technology to drug development, prescription, and non-prescription medical diagnostics and the pairing of drugs …
  • Genome Institute of Singapore-製薬・医療分野:企業M&A・提携分析
    Summary Genome Institute of Singapore (GIS) is a research institute that provides various research programs and services in different areas. The institute concentrates on genomic sciences to improve public health and prosperity in Singapore. It handles the latest in technology and comprises early ca …
  • Sahara Petrochemicals Co:企業の戦略的SWOT分析
    Sahara Petrochemicals Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Profectus BioSciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Profectus BioSciences Inc (Profectus), formerly Maryland Biotherapeutics Inc is a clinical-stage vaccine development company that designs and develops vaccines for infectious diseases and oncolytic vaccines for cancer immunotherapy. The company's products comprise genevax therapeutic vaccine …
  • ARYZTA AG:企業の戦略・SWOT・財務情報
    ARYZTA AG - Strategy, SWOT and Corporate Finance Report Summary ARYZTA AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Tana Exploration Company LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Tana Exploration Company LLC (Tana Exploration) is an oil and gas exploration and development company that develops oil and gas resources. The company's products include natural gas and crude oil. It provides services such as technical support, financial support, and remodeling services. Tan …
  • NCR Corporation:企業のM&A・事業提携・投資動向
    NCR Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NCR Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • NuVista Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    NuVista Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary NuVista Energy Ltd (NuVista) is an oil and gas company that offers exploration, development and production of oil and natural gas reserves. The company conducts its operations in Western Canadian …
  • WellCare Health Plans Inc (WCG)-製薬・医療分野:企業M&A・提携分析
    Summary WellCare Health Plans Inc (WellCare) is a managed care service provider which focuses on providing government-sponsored managed care services to families, children, seniors and individuals with complex medical needs. The company offers Medicaid health plans, Medicare Advantage (MA) coordinat …
  • Milagen Inc:企業の製品パイプライン分析
    Summary Milagen Inc (Milagen) is a medical device company. It provides diagnostic products. The company generates antibody reagents against the human proteome. It discovers, develops and markets non invasive immunodiagnostic products for monitoring, surveillance and detection of cancers. Milagen off …
  • Global Partners LP (GLP)-石油・ガス分野:企業M&A・提携分析
    Summary Global Partners LP (Global Partners) is a midstream logistics and marketing company. It carries out purchasing, selling and logistics of transporting domestic and Canadian crude oil and other products by rail across its virtual pipeline from the mid-continent region of the US and Canada to t …
  • Medipines Corp-医療機器分野:企業M&A・提携分析
    Summary MediPines Corp (Medipines) develops and commercializes advanced respiratory measurement and monitoring devices. It focuses on the development of portable and non-invasive devices based on pulse oximetry technology. The company’s lead product candidate, Oxistimulator, is a respiratory depress …
  • EyeGate Pharmaceuticals Inc (EYEG):企業の財務・戦略的SWOT分析
    Summary EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical and drug delivery company that develops and commercializes products for treating diseases and disorders of the eye. The company’s proprietary technology EyeGate II delivery system, utilizes transscleral iontop …
  • The Interpublic Group of Companies, Inc.:企業の戦略・SWOT・財務情報
    The Interpublic Group of Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Interpublic Group of Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Azomures SA:企業の戦略的SWOT分析
    Azomures SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆